246 related articles for article (PubMed ID: 36192459)
1. Single-nucleus RNA sequencing of midbrain blood-brain barrier cells in schizophrenia reveals subtle transcriptional changes with overall preservation of cellular proportions and phenotypes.
Puvogel S; Alsema A; Kracht L; Webster MJ; Weickert CS; Sommer IEC; Eggen BJL
Mol Psychiatry; 2022 Nov; 27(11):4731-4740. PubMed ID: 36192459
[TBL] [Abstract][Full Text] [Related]
2. Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain.
Purves-Tyson TD; Owens SJ; Rothmond DA; Halliday GM; Double KL; Stevens J; McCrossin T; Shannon Weickert C
Transl Psychiatry; 2017 Jan; 7(1):e1003. PubMed ID: 28094812
[TBL] [Abstract][Full Text] [Related]
3. Hyperactivation of midbrain dopaminergic system in schizophrenia could be attributed to the down-regulation of dysbindin.
Kumamoto N; Matsuzaki S; Inoue K; Hattori T; Shimizu S; Hashimoto R; Yamatodani A; Katayama T; Tohyama M
Biochem Biophys Res Commun; 2006 Jun; 345(2):904-9. PubMed ID: 16701550
[TBL] [Abstract][Full Text] [Related]
4. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain.
Weickert CS; Straub RE; McClintock BW; Matsumoto M; Hashimoto R; Hyde TM; Herman MM; Weinberger DR; Kleinman JE
Arch Gen Psychiatry; 2004 Jun; 61(6):544-55. PubMed ID: 15184234
[TBL] [Abstract][Full Text] [Related]
5. Post-mortem molecular profiling of three psychiatric disorders.
Ramaker RC; Bowling KM; Lasseigne BN; Hagenauer MH; Hardigan AA; Davis NS; Gertz J; Cartagena PM; Walsh DM; Vawter MP; Jones EG; Schatzberg AF; Barchas JD; Watson SJ; Bunney BG; Akil H; Bunney WE; Li JZ; Cooper SJ; Myers RM
Genome Med; 2017 Jul; 9(1):72. PubMed ID: 28754123
[TBL] [Abstract][Full Text] [Related]
6. The neonatal ventral hippocampal lesion model of schizophrenia: effects on dopamine and GABA mRNA markers in the rat midbrain.
Lipska BK; Lerman DN; Khaing ZZ; Weinberger DR
Eur J Neurosci; 2003 Dec; 18(11):3097-104. PubMed ID: 14656305
[TBL] [Abstract][Full Text] [Related]
7. Region-specific permeability of the blood-brain barrier upon pericyte loss.
Villaseñor R; Kuennecke B; Ozmen L; Ammann M; Kugler C; Grüninger F; Loetscher H; Freskgård PO; Collin L
J Cereb Blood Flow Metab; 2017 Dec; 37(12):3683-3694. PubMed ID: 28273726
[TBL] [Abstract][Full Text] [Related]
8. Increased levels of a pro-inflammatory IgG receptor in the midbrain of people with schizophrenia.
Petty A; Glass LJ; Rothmond DA; Purves-Tyson T; Sweeney A; Kondo Y; Kubo S; Matsumoto M; Weickert CS
J Neuroinflammation; 2022 Jul; 19(1):188. PubMed ID: 35841099
[TBL] [Abstract][Full Text] [Related]
9. Metabotropic glutamate receptor 2 and 3 gene expression in the human prefrontal cortex and mesencephalon in schizophrenia.
Ghose S; Crook JM; Bartus CL; Sherman TG; Herman MM; Hyde TM; Kleinman JE; Akil M
Int J Neurosci; 2008 Nov; 118(11):1609-27. PubMed ID: 18853337
[TBL] [Abstract][Full Text] [Related]
10. Inflammation-related transcripts define "high" and "low" subgroups of individuals with schizophrenia and bipolar disorder in the midbrain.
Zhu Y; Owens SJ; Murphy CE; Ajulu K; Rothmond D; Purves-Tyson T; Middleton F; Webster MJ; Weickert CS
Brain Behav Immun; 2022 Oct; 105():149-159. PubMed ID: 35764269
[TBL] [Abstract][Full Text] [Related]
11. Reductions in midbrain GABAergic and dopamine neuron markers are linked in schizophrenia.
Purves-Tyson TD; Brown AM; Weissleder C; Rothmond DA; Shannon Weickert C
Mol Brain; 2021 Jun; 14(1):96. PubMed ID: 34174930
[TBL] [Abstract][Full Text] [Related]
12. Midbrain dopamine D2/3 receptor binding in schizophrenia.
Tuppurainen H; Kuikka JT; Laakso MP; Viinamäki H; Husso M; Tiihonen J
Eur Arch Psychiatry Clin Neurosci; 2006 Sep; 256(6):382-7. PubMed ID: 16783502
[TBL] [Abstract][Full Text] [Related]
13. Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders.
Fiorentino M; Sapone A; Senger S; Camhi SS; Kadzielski SM; Buie TM; Kelly DL; Cascella N; Fasano A
Mol Autism; 2016; 7():49. PubMed ID: 27957319
[TBL] [Abstract][Full Text] [Related]
14. Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia.
Greene C; Kealy J; Humphries MM; Gong Y; Hou J; Hudson N; Cassidy LM; Martiniano R; Shashi V; Hooper SR; Grant GA; Kenna PF; Norris K; Callaghan CK; Islam MD; O'Mara SM; Najda Z; Campbell SG; Pachter JS; Thomas J; Williams NM; Humphries P; Murphy KC; Campbell M
Mol Psychiatry; 2018 Nov; 23(11):2156-2166. PubMed ID: 28993710
[TBL] [Abstract][Full Text] [Related]
15. Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia.
Caravaggio F; Hahn M; Nakajima S; Gerretsen P; Remington G; Graff-Guerrero A
Med Hypotheses; 2015 Oct; 85(4):391-6. PubMed ID: 26118462
[TBL] [Abstract][Full Text] [Related]
16. Iron deficiency alters expression of dopamine-related genes in the ventral midbrain in mice.
Jellen LC; Lu L; Wang X; Unger EL; Earley CJ; Allen RP; Williams RW; Jones BC
Neuroscience; 2013 Nov; 252():13-23. PubMed ID: 23911809
[TBL] [Abstract][Full Text] [Related]
17. Profiling the neurovascular unit unveils detrimental effects of osteopontin on the blood-brain barrier in acute ischemic stroke.
Spitzer D; Guérit S; Puetz T; Khel MI; Armbrust M; Dunst M; Macas J; Zinke J; Devraj G; Jia X; Croll F; Sommer K; Filipski K; Freiman TM; Looso M; Günther S; Di Tacchio M; Plate KH; Reiss Y; Liebner S; Harter PN; Devraj K
Acta Neuropathol; 2022 Aug; 144(2):305-337. PubMed ID: 35752654
[TBL] [Abstract][Full Text] [Related]
18. Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study.
Howes OD; Williams M; Ibrahim K; Leung G; Egerton A; McGuire PK; Turkheimer F
Brain; 2013 Nov; 136(Pt 11):3242-51. PubMed ID: 24097339
[TBL] [Abstract][Full Text] [Related]
19. Exploration of Pericyte-Derived Factors Implicated in Lung Cancer Brain Metastasis Protection: A Pilot Messenger RNA Sequencing Using the Blood-Brain Barrier In Vitro Model.
Ujifuku K; Fujimoto T; Sato K; Morofuji Y; Muto H; Masumoto H; Nakagawa S; Niwa M; Matsuo T
Cell Mol Neurobiol; 2022 May; 42(4):997-1004. PubMed ID: 33136276
[TBL] [Abstract][Full Text] [Related]
20. Support for limited brain availability of tyrosine in patients with schizophrenia.
Bjerkenstedt L; Farde L; Terenius L; Edman G; Venizelos N; Wiesel FA
Int J Neuropsychopharmacol; 2006 Apr; 9(2):247-55. PubMed ID: 15972118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
